Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism

Cancer Cell

Volumn 29, Issue 5, 2016, Pages 751-766

  Cai, Yanyan ^a,b   Crowther, Jonathan ^a,b   Pastor, Tibor ^a,b   Abbasi Asbagh, Layka ^b   Baietti, Maria Francesca ^a,b   De Troyer, Magdalena ^a,b   Vazquez, Iria ^a,b   Talebi, Ali ^b   Renzi, Fabrizio ^a,b   Dehairs, Jonas ^b   Swinnen, Johannes V ^b   Sablina, Anna A ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CERIVASTATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; FATTY ACID; METHOTREXATE; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VINBLASTINE; ANTINEOPLASTIC AGENT;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CHROMOSOME 8P; CHROMOSOME 8P LOSS; CHROMOSOME DELETION; CHROMOSOME LOSS; CONTROLLED STUDY; DRUG RESPONSE; HETEROZYGOSITY LOSS; HUMAN; HYPOXIA; LIPID METABOLISM; OUTCOME ASSESSMENT; POINT MUTATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; BREAST TUMOR; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME 8; DISEASE COURSE; DRUG EFFECTS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MULTICELLULAR SPHEROID; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 8; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LIPID METABOLISM; MULTIVARIATE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPHEROIDS, CELLULAR;

EID: 84975302376     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.04.003     Document Type: Article

References (43)

1. Amari M., Suzuki A., Moriya T., Yoshinaga K., Amano G., Sasano H., Ohuchi N., Satomi S., Horii A. LOH analyses of premalignant and malignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia. Oncol. Rep. 1999, 6:1277-1280.
2. Berenjeno I.M., Nunez F., Bustelo X.R. Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases. Oncogene 2007, 26:4295-4305.
3. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
4. Bertagnolli M.M., Redston M., Compton C.C., Niedzwiecki D., Mayer R.J., Goldberg R.M., Colacchio T.A., Saltz L.B., Warren R.S. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J. Clin. Oncol. 2011, 29:3153-3162.
5. Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
6. Brown J.H., Del Re D.P., Sussman M.A. The Rac and Rho hall of fame - a decade of hypertrophic signaling hits. Circ. Res. 2006, 98:730-742.
7. Buffa F.M., Harris A.L., West C.M., Miller C.J. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J Cancer 2010, 102:428-435.
8. Chuaqui R.F., Sanzortega J., Vocke C., Linehan W.M., Sanzesponera J., Zhuang Z.P., Emmertbuck M.R., Merino M.J. Loss of heterozygosity on the short arm of chromosome-8 in male breast carcinomas. Cancer Res. 1995, 55:4995-4998.
9. Clendening J.W., Pandyra A., Li Z., Boutros P.C., Martirosyan A., Lehner R., Jurisica I., Trudel S., Penn L.Z. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood 2010, 115:4787-4797.
10. Cox C., Bignell G., Greenman C., Stabenau A., Warren W., Stephens P., Davies H., Watt S., Teague J., Edkins S., et al. A survey of homozygous deletions in human cancer genomes. Proc. Natl. Acad. Sci. USA 2005, 102:4542-4547.
11. Davoli T., Xu A.W., Mengwasser K.E., Sack L.M., Yoon J.C., Park P.J., Elledge S.J. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 2013, 155:948-962.
12. Diep C.B., Kleivi K., Ribeiro F.R., Teixeira M.R., Lindgjaerde O.C., Lothe R.A. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Gene Chromosomes Cancer 2006, 45:31-41.
13. Eng C.H., Wang Z.C., Tkach D., Toral-Barza L., Ugwonali S., Liu S.M., Fitzgerald S.L., George E., Frias E., Cochran N., et al. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc. Natl. Acad. Sci. USA 2016, 113:182-187.
14. Galluzzi L., Pietrocola F., Bravo-San Pedro J.M., Amaravadi R.K., Baehrecke E.H., Cecconi F., Codogno P., Debnath J., Gewirtz D.A., Karantza V., et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015, 34:856-880.
15. Ghosh P.M., Ghosh-Choudhury N., Moyer M.L., Mott G.E., Thomas C.A., Foster B.A., Greenberg N.M., Kreisberg J.I. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 1999, 18:4120-4130.
16. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
17. Han S., Park K., Shin E., Kim H.J., Kim J.Y., Kim J.Y., Gwak G. Genomic change of chromosome 8 predicts the response to taxane-based neoadjuvant chemotherapy in node-positive breast cancer. Oncol. Rep. 2010, 24:121-128.
18. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
19. Intergroup Radiation Therapy Oncology Group Trail 9402, Cairncross G., Berkey B., Shaw E., Jenkins R., Scheithauer B., Brachman D., Buckner J., Fink K., Souhami L., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 2006, 24:2707-2714.
20. Jiang W., Ogretmen B. Autophagy paradox and ceramide. Biochim. Biophys. Acta 2014, 1841:783-792.
21. Li C.M., Park J.H., Simonaro C.M., He X., Gordon R.E., Friedman A.H., Ehleiter D., Paris F., Manova K., Hepbildikler S., et al. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 2002, 79:218-224.
22. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., Powell B., Greenberg P., Thomas D., Stone R., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 2006, 355:1456-1465.
23. Macartney-Coxson D.P., Hood K.A., Shi H.J., Ward T., Wiles A., O'Connor R., Hall D.A., Lea R.A., Royds J.A., Stubbs R.S., Rooker S. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 2008, 8:187.
24. Maycotte P., Gearheart C.M., Barnard R., Aryal S., Mulcahy Levy J.M., Fosmire S.P., Hansen R.J., Morgan M.J., Porter C.C., Gustafson D.L., Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014, 74:2579-2590.
25. Melland-Smith M., Ermini L., Chauvin S., Craig-Barnes H., Tagliaferro A., Todros T., Post M., Caniggia I. Disruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia. Autophagy 2015, 11:653-669.
26. Muellner M.K., Uras I.Z., Gapp B.V., Kerzendorfer C., Smida M., Lechtermann H., Craig-Mueller N., Colinge J., Duernberger G., Nijman S.M. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol. 2011, 7:787-793.
27. Rosenfeldt M.T., O'Prey J., Morton J.P., Nixon C., MacKay G., Mrowinska A., Au A., Rai T.S., Zheng L., Ridgway R., et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504:296-300.
28. Salhia B., Kiefer J., Ross J.T.D., Metapally R., Martinez R.A., Johnson K.N., DiPerna D.M., Paquette K.M., Jung S., Nasser S., et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One 2014, 9:e85448.
29. Schiffmann S., Sandner J., Birod K., Wobst I., Angioni C., Ruckhaberle E., Kaufmann M., Ackermann H., Lotsch J., Schmidt H., et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009, 30:745-752.
30. Seitz S., Rohde K., Bender E., Nothnagel A., Pidde H., Ullrich O.M., ElZehairy A., Haensch W., Jandrig B., Kolble K., et al. Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis. Br. J Cancer 1997, 76:983-991.
31. Shaw F.L., Harrison H., Spence K., Ablett M.P., Simoes B.M., Farnie G., Clarke R.B. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J. Mammary Gland Biol. Neoplasia 2012, 17:111-117.
32. Solimini N.L., Xu Q.K., Mermel C.H., Liang A.C., Schlabach M.R., Luo J., Burrows A.E., Anselmo A.N., Bredemeyer A.L., Li M.Z., et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 2012, 337:104-109.
33. Tabares-Seisdedos R., Rubenstein J.L. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol. Psychiatry 2009, 14:563-589.
34. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res. 2012, 18:3524-3531.
35. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997, 11:2295-2322.
36. van den Bent M.J., Carpentier A.F., Brandes A.A., Sanson M., Taphoorn M.J.B., Bernsen H.J.J.A., Frenay M., Tijssen C.C., Grisold W., Sipos L., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J. Clin. Oncol. 2006, 24:2715-2722.
37. van't Veer L.J., Dai H.Y., van de Vijver M.J., He Y.D.D., Hart A.A.M., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
38. Vaupel P., Schlenger K., Knoop C., Hockel M. Oxygenation of human tumors - evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991, 51:3316-3322.
39. Wang W., Macaulay R.J.B. Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines. Can. J. Neurol. Sci. 1999, 26:305-310.
40. Xia Z., Tan M.M., Wong W.W.L., Dimitroulakos J., Minden M.D., Penn L.Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001, 15:1398-1407.
41. Xue W., Kitzing T., Roessler S., Zuber J., Krasnitz A., Schultz N., Revill K., Weissmueller S., Rappaport A.R., Simon J., et al. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc. Natl. Acad. Sci. USA 2012, 109:8212-8217.
42. Yang W.J., Soares J., Greninger P., Edelman E.J., Lightfoot H., Forbes S., Bindal N., Beare D., Smith J.A., Thompson I.R., et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013, 41:D955-D961.
43. Yaremko M.L., Recant W.M., Westbrook C.A. Loss of heterozygosity from the short arm of chromosome-8 is an early event in breast cancers. Gene Chromosomes Cancer 1995, 13:186-191.